Relapsed mesothelioma remains an area of unmet clinical need. The MiST trials platform has been designed as the first ever accelerator for proof of concept early phase clinical trials; our goal is to
1) to drive early drug development in mesothelioma.
2) coordinated exploration of recurrent genomic aberrations that correlate with treatment response
We welcome new partnerships with industry to advance therapy. For further information, please contact Amy King, Mesothelioma Research Programme Manager